Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 4/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.35 |
| ▸ | CDK9 | P50750 | 5/20 | 0.35 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.35 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.34 |
| ▸ | WNT3A | P56704 | 2/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL701995 | 0.91 | SYK (0.40) | SYKGRM5MAPK13MAPK12MAPK11 | |
| SCHEMBL10252204 | 0.91 | SYK (0.48) | SYKCCNT1CDK9PIK3C3 | |
| SCHEMBL7975631 | 0.87 | CDK2 (0.44) | SYKCDK9 | |
| SCHEMBL10255574 | 0.80 | SYK (0.51) | SYKCCNT1CDK9PIK3C3MAPK13 | |
| SCHEMBL10252455 | 0.77 | CDK2 (0.45) | SYKPIK3C3 | |
| SCHEMBL7978465 | 0.77 | CDK2 (0.47) | CDK9 | |
| SCHEMBL700084 | 0.76 | XIAP (0.45) | SYKMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL7975428 | 0.76 | CDK2 (0.47) | — | |
| SCHEMBL10252168 | 0.74 | XIAP (0.47) | SYKCDK9MAPK10 | |
| SCHEMBL7976848 | 0.74 | CDK2 (0.53) | SYKCCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124764-B2 | Fused heterocyclyc inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2010009155-A2 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC7 | SYK 3840/4885GRM5 2543/4885CCNT1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.